Specify a stock or a cryptocurrency in the search bar to get a summary
Zealand Pharma A/S
22ZZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark. Address: Sydmarken 11, Søborg, Denmark, 2860
Analytics
WallStreet Target Price
204.75 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 22Z
Dividend Analytics 22Z
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 22Z
Stock Valuation 22Z
Financials 22Z
Results | 2019 | Dynamics |